Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2017

View Archived Issues

European Commission approves new single-dose delivery option for Repatha

Lanthio Pharma initiates first-in-human trial of MOR-107

Symptom improvement seen with etrolizumab in phase III study

Valeant Pharmaceuticals enters another EGP-437 licensing agreement with EyeGate

Researchers present safety, efficacy data for hydroxychloroquine plus aldesleukin in mRCC

Gilead tests novel non-catalytic site integrase inhibitor GS-9822 in vivo

Sarepta Therapeutics agrees to sell priority review voucher to Gilead Sciences

CureGrail launches with focus on diabetes

Adapt Pharma applies for E.U. approval of naloxone HCl nasal spray

FDA accepts Carbavance NDA for priority review

CohBar's lead candidates show promise in preclinical studies in NASH model

Protalex gives update on studies of PRTX-100 in ITP

Phase II results do not support further development of topical CD-101 for acute VVC

MJFF awards grant to FORMA Therapeutics for Parkinson's research

Pfizer's BLA for inotuzumab ozogamicin granted priority review by FDA

EMA grants orphan drug designation to LYS-GM101 for the treatment of GM1 gangliosidosis

Cellect Biotechnology reports positive final results from clinical trial of ApoGraft

Apitope reports results from phase IIa study of ATX-MS-1467

Trevena reports promising topline phase III data on oliceridine

FDA grants fast track status to Vericel's ixmyelocel-T

Novel Wnt signaling and IL-6 production inhibitors patented by Samumed

NewLink Genetics presents phase I data on HyperAcute Renal immunotherapy in patients with RCC

XBiotech can continue phase III study of Xilonix for treatment of colorectal cancer

VBL Therapeutics reports full results from exploratory phase II study of VB-111

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...